Opinion|Videos|July 22, 2024
Transition of Care in Young Adults With Spinal Muscular Atrophy
Medical professionals explore the challenges and considerations associated with patients with spinal muscular atrophy (SMA) transitioning to independent living, emphasizing the importance of maintaining continuity of care and addressing potential adherence issues to ensure optimal disease management.
Advertisement
Episodes in this series
- When transitioning care from a parent to patients living on their own, what are some important considerations to ensure continuity of care?
- What gaps do you observe in your practice and how do you mitigate them?
Advertisement
Related to this article
One-year KYSA-6 data showed KYV-101, a CD19 CAR T-cell therapy, produced durable, drug-free responses in generalized myasthenia gravis.
The FDA has granted Scholar Rock's apitegromab fast track designation for the treatment of patients with living facioscapulohumeral muscular dystrophy as the company's phase 2 FORGE study dosing begins.
Ulefnersen met its primary end point in the phase 3 FUSION trial, providing the first placebo-controlled evidence for a genetically targeted therapy in FUS-ALS.
The CHMP recommended approval of gefurulimab (Klygefa), a weekly, self-administered C5 inhibitor, for AChR-antibody-positive generalized myasthenia gravis in the EU.
Here's some of what is coming soon to NeurologyLive® this week.
The approval, based on phase 3 IB1001-303 trial data showing consistent SARA scale improvement, makes levacetylleucine the first treatment approved specifically for ataxia-telangiectasia.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 18, 2026.
Brian Lin, PhD, discussed the current evidence linking football participation with ALS, the questions that remain unanswered, and how emerging research may help clarify the association.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Grants Fast Track Designation to Apitegromab for Facioscapulohumeral Muscular Dystrophy
2
Closing the Gaps in Cluster Headache Care: Jennifer Fokas, MD; Minali Nigam, MD
3
Ulefnersen Meets Primary End Point in Phase 3 FUSION Trial for FUS-ALS
4
Qihuang Needle Acupuncture Improves Motor and Nonmotor Parkinson Disease Symptoms
5